Healthcare Industry News: Johnson & Johnson
News Release - October 10, 2018
Tris Pharma Announces Hiring of Chief Commercial OfficerMONMOUTH JUNCTION, N.J., Oct. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based therapeutic products that address unmet patient needs, today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris' expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.
Mr. Curatolo has more than 20 years of commercial brand leadership experience with large, medium and start-up pharmaceutical companies. During his career, he has held positions of increasing responsibility in sales, marketing, strategy and sales operations. He has spent most of the last 2 decades working on or leading ADHD brands, including two of the only three blockbuster products in the category. He spent 10 years at Shire Pharmaceuticals, preceded by 10 years at Johnson & Johnson. He holds an M.B.A. in Marketing Management from St. John's University and a B.A. in Environmental Economics from Rutgers University.
"Tom's track record, especially within the ADHD category, coupled with his extensive experience in pharmaceutical sales, sales management and marketing, makes him an ideal leader for our expanded ADHD business," said Ketan Mehta, Founder and Chief Executive Officer of Tris. "Along with Barry Herman, M.D., M.M.M., Tris' Chief Medical Officer, who is building a world-class Medical Affairs team, we are poised to become a leading ADHD Company."
"I am honored to have the opportunity to lead Tris' commercial organization, and recognize that with our recent acquisition, we are now positioned to establish Tris as a leader in the ADHD category," said Mr. Curatolo. "I look forward to working with my colleagues at Tris to help improve the lives of patients we serve."
About Tris Pharma
Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that address unmet patient needs. Tris has pioneered the delivery of sustained release in liquid, chewable, orally-disintegrating tablet, and strip dosage forms that can benefit a wide variety of patients and their unique needs. Tris' research, manufacturing, and commercial facilities are located in Central New Jersey. For more information, please visit www.trispharma.com
Source: Tris Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.